Sign inCreate account

Report workspace

Add to folder
NCT00140218COMPLETEDanonymous

Futility Study of R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis

Sponsor

Source record

Bennett, James P., Jr., M.D., Ph.D.

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

R(+) pramipexole dihydrochloride monohydrate

Indication / condition

AI-normalized

Amyotrophic Lateral Sclerosis

Intervention

Source record

R(+) pramipexole dihydrochloride monohydrate

Source & freshness

Source record

NCT ID

NCT00140218

Original source

ClinicalTrials.gov

Source last updated

Jan 08, 2008

Ingested at

Jun 17, 2026

Internal sync

Jun 17, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00140218

Title

Futility Study of R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis

Sponsor

Bennett, James P., Jr., M.D., Ph.D.

Status

COMPLETED

Phase

PHASE1

Condition raw

Amyotrophic Lateral Sclerosis

Condition normalized

Amyotrophic Lateral Sclerosis

Modality raw

small molecule

Modality normalized

small molecule

Target raw

R(+) pramipexole dihydrochloride monohydrate

Target normalized

R(+) pramipexole dihydrochloride monohydrate

Interventions

R(+) pramipexole dihydrochloride monohydrate

Public preview

Source record

The hypothesis of this study is that treatment with R(+) pramipexole at 30 mg/day will alter the slope of decline in ALS functional rating scale over the course of 6 months. ALS patients at an early stage of disease will be observed for 3 months after enrollment and then treated with drug for 6 months.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Futility Study of R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 17, 2026

NCT ID

NCT00140218

Status

COMPLETED

Phase

PHASE1

Sponsor

Bennett, James P., Jr., M.D., Ph.D.

Executive brief

Investment-Ready Snapshot

The hypothesis of this study is that treatment with R(+) pramipexole at 30 mg/day will alter the slope of decline in ALS functional rating scale over the course of 6 months. ALS patients at an early stage of disease will be observed for 3 months after enrollment and then treated with drug for 6 months.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 08, 2008
Internal syncJun 17, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00140218

Indication

Amyotrophic Lateral Sclerosis

Modality

small molecule

Target

R(+) pramipexole dihydrochloride monohydrate

Intervention

R(+) pramipexole dihydrochloride monohydrate

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.